Download Free Medical What’s New in Neurology-Recent Discoveries PowerPoint Presentation

What’s New in Neurology-Recent Discoveries PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Neurology, which is titled "What’s New in Neurology? - Recent Discoveries", to know about the new discoveries in neurology.

Tags : Neurology, Discoveries

Published on : Aug 18, 2021 | Views : 2072 | Downloads : 10

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

ppt slide no 1 content not found
Slide 2-

Holly E. Hinson, MD, MCR, FAAN Associate Professor of Neurology and Emergency Medicine Oregon Health & Science University What’s New in Neurology? Recent Discoveries Slide 1 Courtney Takahashi, MD MCR Assistant Professor of Neurology and Neurosurgery Boston University Medical Center
Slide 3-

Slide 2 Overview: Updates in Neurology Neurologists are traditionally characterized as “diagnosticians” but this stereotype is rapidly changing! In the past 5 years, new treatments and diagnostic advances have changed every subspecialty of neurology.
Slide 4-

Updates: Vascular Neurology Slide 3
Slide 5-

Slide 4 Vascular Neurology: Background Before 1995: Stroke patients are managed for secondary prevention only 1996: tPA approved for the treatment of acute stroke, shown to improve functional outcomes (modified rankin scores) at 3 months 2004: Thrombectomy devices approved 2012: Stent-trievers introduced
Slide 6-

Slide 5 Vascular Neurology: Background
Slide 7-

Slide 6 Expanding the Window for Acute Stroke Treatment with Imaging CT-perfusion and MR perfusion are more readily accessible to evaluate patients outside the classic 6-hour time window for intervention Donahue. Journal of Neuroradiology Volume 42, Issue 1, 2015
Slide 8-

Hyperacute MRI May Change tPA Time Windows Slide 7 NEJM published data that suggest MRI mismatch may be able to supplement and possibly replace time windows based on last known well times.
Slide 9-

Slide 8 Results: MRI Guided Thrombolysis for Stroke / WAKE up Gerloff et al, MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset, New England Journal of Medicine, 16 May 2018
Slide 10-

Slide 9 Improving the Success of Thrombectomy for Acute Stroke
Slide 11-

Slide 10 IN 2015: New Era of Acute Stroke Therapy Five recent randomized controlled trials Clear efficacy and overwhelming benefit: Intra-arterial thrombectomy Standard of care: Class I, level of evidence A
Slide 12-

Slide 11 Summary of Thrombectomy Trials Gory et al, Stent retriever thrombectomy for acute ischemic stroke: Indications, results, and management in 2015, Diagnostics and Interventional Imaging (2016) 97, 141-149
Slide 13-

Updates: Traumatic Brain Injury Slide 12
Slide 14-

Background: Chronic Traumatic Encephalopathy (CTE) CTE is a progressive tauopathy that occurs after repeated traumatic brain injury Pathological changes associated with the disease and the clinical manifestations associated with each pathological stage Slide 13 Stage I: Headache, loss of attention, concentration  Stage 2: Depression, memory loss  Stage 3: Executive dysfunction, cognitive impairment  Stage 4: Dementia, word finding difficulty, aggression McKee et al, The spectrum of disease in chronic traumatic encephalopathy, Brain, 2013: Jan 136 (1):43-63
Slide 15-

Background: Images of CTE Slide 14
Slide 16-

Traumatic Brain Injury: New Innovations 50 million people per year worldwide suffer from TBI Given long term effects with CTE, TBI research deserves promotion Many TBI sufferers, however, do not have access to CT scanner Slide 15
Slide 17-

Adults with GCS 9-15 within 12 hours of injury Alert TBI: Banyan UCH-L1/GFAP Detection Assay Correlation of assay result with absence of acute intracranial lesions Bazarian. Lancet Neurol. 2018 Jul 24 Detecting Traumatic Brain Injury
Slide 18-

Can blood-based biomarkers (GFAP, UCH-L1) predict head injury after TBI? Primary study outcomes: test sensitivity and negative predictive value (NPV) 1977 patients enrolled; sensitivity 0.976 and NPV 0.996. Less than 1% of patients had a positive CT scan when the test was negative. 17 Bazarian et al, Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study, The Lancet Neurology, Vol 17, issue 9, September 2018, 782-789 ALERT-TBI: Results
Slide 19-

Updates: Neuromuscular Disease 18
Slide 20-

Background: Spinal Muscular Atrophy Slide 19 Genetic disorders that cause degeneration of anterior horn cells, leading to weakness and muscle atrophy Four phenotypes defined by severity and age of onset. 60% of cases occur before age 1 and classify most severe form Image courtesy of Prime Health Channel: Spinal Muscular Atrophy
Slide 21-

Treatments for Spinal Muscular Atrophy 20 Degenerative neuromuscular disorder due to insufficient SMN1 protein Manifests at truncal weakness before age 1 in the most severe cases. Prognosis historically poor—usually death in childhood. Crawford et al, Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. Journal of Clinical Investigation. 2018; 128 (8): 3219-3227
Slide 22-

Treatment Options: Spinal Muscular Atrophy Slide 21 Nusinersen/Spinraza (ASO) alters gene splicing mechanisms in pre-mRNA quantities of SMN2 proteins Avexis-101 (scAAV9-SMN) delivers exogenous SMN1 cDNA through viral vectors
Slide 23-

Slide 22 Treatment Options: Spinal Muscular Atrophy
Slide 24-

Background: Myasthenia Gravis Slide 23 Myasthenia gravis is an autoimmune disease that prevents transmission between motor neuron and muscle Traditional treatments include symptom control with pyridostigmine and immunosuppression with steroids, azathioprine, and mycophenolate mofetil
Slide 25-

Myasthenia Gravis: Eculizumab Slide 24 Eculizumab is the first FDA-approved drug since the 1950s for the treatment of refractory, generalized, antibody positive myasthenia gravis Originally distributed for the treatment of paroxysmal nocturnal hemoglobinuria Blocks complement (C5) Advantages include FASTER onset and evaluation for efficacy compared to traditional immunosuppressants
Slide 26-

Updates: Movement Disorders Slide 25
Slide 27-

Slide 26 Background: Dystonia Dystonia consists of abnormal, sustained muscle contractions, usually in agonist and antagonist groups, which lead to odd posturing First line medications: anticholingergics, benzodiazepines, baclofen, PT/OT Deep brain stimulation may be considered for treatment
Slide 28-

Background: Dystonia Images Slide 27 Globus Pallidus
Slide 29-

Deep Brain Stimulation for Generalized Dystonia http://www.youtube.com/watch?v=wk3wz4gQZ3Q
Slide 30-

Thank You
Slide 31-

Acknowledgement to Dr. Mohamad Abdalkader from Boston University Medical Center for assistance with these slides